Education and Training

Radiation Therapy Residency

Medical Students

Medical Physics Residency

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY)

The Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY) trial is the first ever international multi-center randomized controlled trial in bone cancer surgery. In order to avoid amputation for bone cancer in the leg, complex limb-saving operations are performed. However, infections with devastating complications following surgery are common. Surgeons from across the world will randomize patients to receive either short- or long-duration antibiotic regimens after surgery with the goal of identifying the best regimen to reduce these infections.

Stanford is currently accepting patients for this trial.

Stanford Investigator(s):

Intervention(s):

  • drug: 24-Hour Prophylactic Cefazolin* Antibiotic Regimen
  • drug: 5-Days Prophylactic Cefazolin* Antibiotic Regimen

Eligibility


Inclusion Criteria:

   - primary bone malignancies or aggressive benign bone tumors of the femur or tibia,
   soft-tissue sarcomas which have invaded the femur or tibia, or oligometastatic bone
   disease of the femur or tibia in a patient expected to live at least one year
   post-operatively; and

   - treatment by surgical excision and endoprosthetic replacement of the femur or tibia.

Exclusion Criteria:

   - current known Methicillin-resistant Staphylococcus Aureus (MRSA) colonization;

   - current known Vancomycin Resistant Enterococcus (VRE) colonization;

   - documented anaphylaxis or angioedema to penicillin or cefazolin (Ancef);

   - current surgical procedure is a revision surgery for implant failure or infection;

   - prior local infection within the surgical field of the affected limb;

   - current known immunologically-deficient disease conditions (not including recent
   chemotherapy);

   - known renal insufficiency with estimated creatinine clearance (eGRF) of less than 54
   mL/min;

   - reconstruction to include structural allograft;

   - enrolled in a competing study; and

   - weight of less than or equal to 45 kg (for sites using cefuroxime only).

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Recruiting